|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
The breast cancer cell line (T47D) was grown in the RPMI 1640 medium, supplemented with 10% FBS.
|
25435410 |
2016 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
The T47D breast cancer cell line was grown in RPMI 1640 supplemented with 10% FBS.
|
27268613 |
2016 |
|
Malignant neoplasm of breast
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Combining microRNA (miRNA) assay, functional characterization, mechanistic studies with clinical validation, we identify FBX8 as a CRC metastasis suppressor downstream of miR-223, a metastasis promoting miRNA that is transcriptionally regulated by Myocyte enhancer factor (MEF2A). mTOR is a substrate of FBX8 for ubiquitin-mediated degradation and is required for FBX8 induced cell proliferation and invasion in CRC cells.
|
27916606 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Downregulation of BRD4 inhibited FBS-induced migration and invasion of human RA-FLS.
|
26093279 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Knocking down FBX8 obviously promoted proliferation and invasion in BGC823 cells, while over-expression of FBX8 in SGC7901 and AGS cells had the opposite effects.
|
25801334 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Over-expression of FBX8 decreased proliferation, migration and invasion in HepG2 and 97H cells, while knock-down of FBX8 in 7721 cells showed the opposite effect.
|
23826080 |
2013 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
A cell proliferation assay was performed using the cell counting kit-8 (CCK-8) method, cell migration was assessed by a cell wound-healing assay and cell invasion was evaluated in microchemotaxis chambers using FBS as the chemotactic stimulus.
|
23007325 |
2012 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Together, these results suggest that FBX8 is a novel c-Myc binding protein and that c-Myc induces cell invasive activity through the inhibition of FBX8 effects on ARF6 function during cell invasion.
|
20848231 |
2010 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
By using folic acid (FA) as a recognition element, a total of 100 cancer cells (HeLa) can be distinguished in 1 mL culture medium with 10% FBS.
|
31830181 |
2020 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
F-box only protein 8 (FBX8), as a critical component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligases, has been associated with several malignancies through interacting with a member of proteins.
|
31024008 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In particular hormones found in FBS act globally on cancer cell physiology and influence transcriptome and metabolome.
|
29455394 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Herein, tiny LaF<sub>3</sub> and PrF<sub>3</sub> nanoparticles in DMEM+FBS suspensions stimulated tumour cell growth in three different human cell lines (A549, SW837 and MCF7).
|
30465280 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Moreover, exogenous BLBP was found to downregulate the tumor suppressors p21 and p16 in the 1% FBS culture medium, but only p21 in the 10% FBS culture medium.
|
29048614 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
F-box only protein 8 (FBX8), a novel component of F-box proteins, is down-regulated in several tumors and closely correlates with tumor progression.
|
27916606 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
F-box only protein 8 (FBX8), a novel component of F-box proteins, has recently been observed in several malignancies.
|
25801334 |
2015 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In vivo functional assays showed FBX8 suppressed tumor growth and pulmonary metastatic potential in mice.
|
23826080 |
2013 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The improvements include: (1) combined mechanical and enzymatic disaggregation of the tumor samples, (2) initiation of short-term cultures in plastic flasks that have a Primaria-modified tissue culture surface or have been coated with Vitrogen 100, (3) use of serum-free growth medium, CDM-5, but with temporary (24 hours) enrichment with 20% FBS if rapid cell attachment is not achieved, (4) partial and sequential harvesting of the cultures, and (5) use of minimal volumes of hypotonic and fixative solutions during harvesting.
|
1384657 |
1992 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
By using folic acid (FA) as a recognition element, a total of 100 cancer cells (HeLa) can be distinguished in 1 mL culture medium with 10% FBS.
|
31830181 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
The results of the current study had shown that after supplementation with 100 mg/day of CoQ<sub>10</sub> for 12 weeks, serum values of FBS, HOMA-IR, TC, LDL-C and ferritin were decreased and values of HDL-C were increased in women with T2DM.
|
29365333 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
<b>Abbreviations used:</b> T2DM: Type-2 diabetes mellitus; RRE: Rhinacanthins-rich extract; RC: Rhinacanthin-C; RD: Rhinacanthin-D; RN: Rhinacanthin-N; α-MEM: α-Minimum essential medium; DMEM: Dulbecco's modified Eagle's medium; HS: Horse serum; FBS: Fetal bovine serum; BSA: Bovine serum albumin; IBMX: 3-isobutyl-1-methylxanthine; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; GO: Glucose oxidase; NMR: Nuclear magnetic resonance; HPLC: High-performance liquid chromatography.
|
29491638 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In particular hormones found in FBS act globally on cancer cell physiology and influence transcriptome and metabolome.
|
29455394 |
2018 |